Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Joel Beatty
BAIRD
Joel Beatty
Wall Street Analyst
★☆☆☆☆
#2390
on 13Foresight · ranked by our own returns
52%
Success Rate
+23.7%
Average Return
28 of 54 calls profitable · +0.4% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 52% of Joel Beatty's ratings turned a profit when each position was held for 1 year — averaging +23.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

8 Buy 1 Hold 0 Sell
Joel's Stock Coverage 57 ratings · 2026-06-19
Company Date Position Consensus Price Target 1-Yr Return
AMLX
Amylyx Pharmaceuticals Inc
Oct 16, 2025 BUY Strong Buy
+46.8% avg upside
13 analysts
$19.00
21.31% Upside
+1.3%
LRMR
Larimar Therapeutics
Sep 30, 2025 BUY Strong Buy
+413.5% avg upside
21 analysts
$7.00
92.39% Upside
+5.3%
ACAD
ACADIA Pharmaceuticals
Sep 24, 2025 BUY Strong Buy
+66.0% avg upside
42 analysts
$31.00
43.30% Upside
+1.6%
DNTH
Dianthus Therapeutics
Sep 09, 2025 BUY Strong Buy
+8.9% avg upside
29 analysts
$67.00
18.84% Downside
+121.8%
PTCT
PTC Therapeutics
Aug 08, 2025 BUY Strong Buy
-1.4% avg upside
29 analysts
$70.00
11.39% Downside
+73.0%
JAZZ
Jazz Pharmaceuticals
Aug 07, 2025 BUY Strong Buy
-1.8% avg upside
35 analysts
$160.00
28.80% Downside
+105.7%
ARGX
Argenx Se
Aug 01, 2025 BUY Strong Buy
-15.9% avg upside
46 analysts
$788.00
10.30% Downside
+31.0%
TSE:FURY
Fury Gold Mines
Jun 26, 2025 BUY Strong Buy
+385.8% avg upside
4 analysts
·
AXSM
Axsome Therapeutics
Jun 10, 2025 BUY Strong Buy
-10.5% avg upside
28 analysts
$157.00
37.40% Downside
+124.1%
NGNE
Neurogene
May 16, 2025 HOLD Strong Buy
+55.9% avg upside
23 analysts
$24.00
23.97% Downside
+65.8%
EDIT
Editas Medicine
May 13, 2025 BUY Buy
+420.3% avg upside
33 analysts
$4.00
48.64% Upside
+93.3%
DNLI
Denali Therapeutics
May 08, 2025 BUY Strong Buy
+60.2% avg upside
24 analysts
$29.00
24.44% Upside
+36.0%
PRAX
Praxis Precision Medicines
May 05, 2025 BUY Strong Buy
+92.1% avg upside
24 analysts
$76.00
73.13% Downside
+755.5%
ALKS
Alkermes
May 02, 2025 BUY Strong Buy
-17.5% avg upside
34 analysts
$41.00
8.83% Downside
+5.0%
DFTX
Definium Therapeutics
Mar 07, 2025 BUY Strong Buy
+45.0% avg upside
20 analysts
$16.00
34.61% Downside
+158.6%
CTNM
Contineum Therapeutics, Inc. Class A
Mar 07, 2025 BUY Strong Buy
+70.7% avg upside
8 analysts
$16.00
33.93% Upside
+105.0%
CPRX
Catalyst Pharma
Mar 03, 2025 BUY Strong Buy
-17.0% avg upside
15 analysts
$32.00
1.93% Upside
+7.2%
INMB
Inmune Bio
Feb 24, 2025 HOLD Buy
+753.7% avg upside
11 analysts
-83.2%
CYPH
Cypherpunk Technologies
Feb 24, 2025 HOLD Buy
+1087.0% avg upside
9 analysts
·
DRUG
Bright Minds Biosciences
Nov 25, 2024 BUY Strong Buy
+120.9% avg upside
10 analysts
$75.00
23.54% Upside
+69.8%
CLDI
Calidi Biotherapeutics
Nov 17, 2024 BUY Strong Buy
+6314.1% avg upside
3 analysts
$2.50
1380.18% Upside
-94.7%
IMMP
Immutep
Nov 14, 2024 BUY Strong Buy
+1343.0% avg upside
7 analysts
$7.00
1770.61% Upside
-11.5%
NRIX
Nurix Therapeutics
Jul 11, 2024 BUY Strong Buy
+76.3% avg upside
26 analysts
$26.00
48.07% Upside
-43.5%
ARCT
Arcturus Therapeutics
May 10, 2024 HOLD Buy
+291.8% avg upside
35 analysts
-59.7%
GERN
Geron
May 02, 2024 HOLD Strong Buy
+240.0% avg upside
19 analysts
$4.50
257.19% Upside
-65.1%
ARWR
Arrowhead Pharmaceuticals
Jan 05, 2024 HOLD Strong Buy
-19.1% avg upside
26 analysts
-44.4%
SNDX
Syndax Pharmaceuticals
Jan 05, 2024 HOLD Strong Buy
+88.7% avg upside
27 analysts
-33.1%
COGT
Cogent Biosciences
Dec 12, 2023 BUY Strong Buy
+7.4% avg upside
26 analysts
$14.00
59.55% Downside
+87.4%
BYSI
Beyondspring
Nov 07, 2023 BUY Hold
+400.8% avg upside
8 analysts
$1.25
22.44% Downside
+95.4%
RARE
Ultragenyx Pharmaceutical
Nov 02, 2023 BUY Strong Buy
+142.0% avg upside
36 analysts
$57.00
107.81% Upside
+39.3%
BMRN
BioMarin Pharmaceutical
Nov 01, 2023 BUY Strong Buy
+72.7% avg upside
52 analysts
$127.00
132.18% Upside
-20.7%
PLRX
Pliant Therapeutics
Sep 26, 2023 BUY Buy
+1820.7% avg upside
21 analysts
$44.00
3693.09% Upside
-33.0%
CRDF
Cardiff Oncology
Sep 26, 2023 BUY Strong Buy
+736.8% avg upside
18 analysts
$5.00
313.25% Upside
+70.4%
VAXX
Vaxxinity Inc
Sep 07, 2023 BUY Buy
+73233.3% avg upside
4 analysts
$7.00
46566.63% Upside
-98.3%
IDYA
IDEAYA Biosciences
Nov 17, 2022 BUY Strong Buy
+55.3% avg upside
29 analysts
$24.00
23.13% Downside
+67.1%
VIR
Vir Biotechnology
Aug 09, 2022 HOLD Strong Buy
+185.4% avg upside
16 analysts
$25.00
172.94% Upside
-53.2%
KYNB
Kyntra Bio
Mar 02, 2021 BUY Buy
+369.6% avg upside
14 analysts
$51.00
661.16% Upside
-64.8%
ALNY
Alnylam Pharma
Feb 12, 2021 HOLD Strong Buy
+23.4% avg upside
51 analysts
$175.00
37.10% Downside
-4.5%
VNDA
Vanda
Feb 11, 2021 HOLD Strong Buy
+253.1% avg upside
13 analysts
$18.00
210.39% Upside
-27.6%
SRPT
Sarepta Therapeutics
Jan 12, 2021 HOLD Buy
+246.5% avg upside
49 analysts
$108.00
516.05% Upside
-15.3%
HALO
Halozyme
Dec 11, 2020 HOLD Strong Buy
-13.7% avg upside
20 analysts
$41.00
40.13% Downside
-16.0%
AMRN
Amarin
Dec 07, 2020 BUY Buy
-47.2% avg upside
18 analysts
$7.00
56.28% Downside
-27.4%
IONS
Ionis Pharmaceuticals
Sep 08, 2020 BUY Strong Buy
+13.3% avg upside
43 analysts
$74.00
0.19% Downside
-29.9%
MIRM
Mirum Pharmaceuticals
Sep 01, 2020 BUY Strong Buy
+7.5% avg upside
21 analysts
$31.00
71.07% Downside
·
DBVT
DBV Technologies SA - American
Aug 05, 2020 BUY Strong Buy
+55.4% avg upside
15 analysts
$4.00
74.34% Downside
+89.9%
ELOX
Eloxx Pharmaceuticals
Jun 10, 2020 HOLD Strong Buy
+153.9% avg upside
8 analysts
$4.00
71.42% Downside
-46.1%
NERV
Minerva Neurosciences
Jun 01, 2020 BUY Buy
+68.3% avg upside
8 analysts
$6.00
34.23% Upside
-29.4%
TPST
Tempest Therapeutics
May 29, 2020 BUY Buy
+1662.1% avg upside
18 analysts
$6.00
387.77% Upside
-55.3%
XFOR
X4 Pharmaceuticals
May 18, 2020 BUY Strong Buy
+496.4% avg upside
15 analysts
$14.00
231.78% Upside
-16.4%
ESPR
Esperion
May 07, 2020 BUY Buy
+701.2% avg upside
22 analysts
$56.00
1677.78% Upside
-49.5%
MDGL
Madrigal Pharmaceuticals
Mar 05, 2020 BUY Strong Buy
-5.8% avg upside
31 analysts
$155.00
69.43% Downside
+27.6%
INO
Inovio Pharmaceuticals
Sep 15, 2019 BUY Buy
+808.5% avg upside
19 analysts
$4.00
258.71% Upside
+406.7%
ATYR
aTyr Pharma
Aug 30, 2019 HOLD Buy
+2016.8% avg upside
17 analysts
$3.75
732.46% Upside
+34.0%
SLDB
Solid Biosciences
Aug 29, 2019 SELL Strong Buy
+92.3% avg upside
23 analysts
$6.00
28.06% Downside
+71.9%
IBRX
ImmunityBio
May 30, 2019 SELL Strong Buy
+55.2% avg upside
12 analysts
$0.80
89.19% Downside
-529.9%
KURA
Kura Oncology
May 24, 2019 BUY Strong Buy
+162.8% avg upside
26 analysts
$25.00
151.79% Upside
-1.7%
NVAX
Novavax
May 06, 2019 BUY Buy
+154.0% avg upside
20 analysts
$19.00
108.05% Upside
+86.3%
🔒 52 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Joel Beatty — Frequently Asked Questions
How accurate are Joel Beatty's stock ratings?
Based on the calls 13Foresight could measure, about 52% of Joel's ratings were profitable over a one-year hold, with an average return of +23.7% per rating, or +0.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Joel ranked on 13Foresight?
Joel Beatty is currently ranked #2390 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Joel cover?
Joel most recently has ratings on AMLX, LRMR, ACAD, DNTH, PTCT, JAZZ, ARGX, TSE:FURY, AXSM, NGNE, EDIT, DNLI and 45 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.